Complete Response News Today

Deep Dive - Theralase Technologies Inc

/PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics,...

Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic...

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter and full year ended Decem...

Strategic shift prioritizes the development of GLP-1 implants for the treatment of obesity and chronic weight management Positive NPM-115 preclinical weight loss data comparable to semaglutide,...

Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, highlighted recent progress across the companys immuno-oncology portfolio....

The approval allows the therapy to be used in a reduced dosing of 1.5 milligrams per kilogram every two weeks, in patients who have achieved and maintained a complete response or better for a minimum of six months. Tecvayli was first approved in October 2022 for the treatment of adults with multiple myeloma that is hard to treat, or has come back after receiving at least four prior lines of certain classes of therapies. Multiple myeloma is a type of blood cancer that affects types of white blo...

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

A study from China found that tofacitinib was an effective treatment for alopecia areata (AA), with most patients achieving complete or partial hair regrowth and experiencing tolerable side effects.

Hemogenyx Pharmaceuticals PLC Announces Submission of Complete Response ...